We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Vaccine Therapy in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00091273
Recruitment Status : Completed
First Posted : September 9, 2004
Results First Posted : June 20, 2014
Last Update Posted : June 20, 2014
Information provided by (Responsible Party):

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Conditions: Ovarian Cancer
Primary Peritoneal Cavity Cancer
Interventions: Biological: incomplete Freund's adjuvant
Biological: ovarian cancer peptide vaccine
Biological: sargramostim
Biological: tetanus toxoid helper peptide
Procedure: adjuvant therapy

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
Single Arm No text entered.

Participant Flow:   Overall Study
    Single Arm

  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Single Arm No text entered.

Baseline Measures
   Single Arm 
Overall Participants Analyzed 
[Units: Participants]
[Units: Participants]
<=18 years   0 
Between 18 and 65 years   7 
>=65 years   2 
[Units: Years]
Mean (Standard Deviation)
 57  (13) 
[Units: Participants]
Female   9 
Male   0 
Region of Enrollment 
[Units: Participants]
United States   9 

  Outcome Measures

1.  Primary:   Safety of the Vaccine   [ Time Frame: Days 1,8,15,22,29,36,43,50 ]

2.  Primary:   Measure of Tumor-antigen-specific Immunity in SIN by ELIspot Assay   [ Time Frame: Day 22 ]

3.  Secondary:   Measure of Tumor-antigen-specific Immunity in PBMC by Elispot Assay   [ Time Frame: Days 1,8,15,22,29,36,43,50 and Month 3 ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.

Results Point of Contact:  
Name/Title: Craig L. Slingluff, MD
Organization: University of Virginia
phone: 434-924-1730
e-mail: cls8h@virginia.edu

Responsible Party: Amir Jazaeri, University of Virginia
ClinicalTrials.gov Identifier: NCT00091273     History of Changes
Other Study ID Numbers: 11276
First Submitted: September 7, 2004
First Posted: September 9, 2004
Results First Submitted: May 19, 2014
Results First Posted: June 20, 2014
Last Update Posted: June 20, 2014